T M L Tong, M Fiocco, J J van Duijn-de Vreugd, J Lutjeboer, F M Speetjens, F G J Tijl, M E Sitsen, R W M Zoethout, C H Martini, A L Vahrmeijer, R W van der Meer, C S P van Rijswijk, A R van Erkel, E Kapiteijn, M C Burgmans
PURPOSE: Percutaneous hepatic perfusion with melphalan (M-PHP) is a minimally invasive therapy with proven efficacy in patients with uveal melanoma (UM) liver metastases. M-PHP is associated with a short hospital admission time and limited systemic side effects. In this study, we assessed quality of life (QoL) in UM patients treated with M-PHP. MATERIALS AND METHODS: A prospective, single-center study including 24 patients treated with M-PHP for UM metastases to the liver...
April 8, 2024: Cardiovascular and Interventional Radiology